lysine Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| 1622 | 56-87-1 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
An essential amino acid. It is often added to animal feed.
Legend: OFP - off patent OFM - off market ONP - on patent |
Drug dosage:
None
ADMET properties:
None
Approvals:
| Date | Agency | Company | Orphan |
|---|---|---|---|
| None | FDA |
FDA Adverse Event Reporting System (Female)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Foetal growth restriction | 42.64 | 17.87 | 16 | 2982 | 6551 | 46676513 |
| Infantile apnoea | 32.69 | 17.87 | 8 | 2990 | 768 | 46682296 |
| Selective eating disorder | 26.27 | 17.87 | 8 | 2990 | 1737 | 46681327 |
| Stomatitis | 24.74 | 17.87 | 26 | 2972 | 68271 | 46614793 |
| Cerebral haemorrhage | 22.83 | 17.87 | 17 | 2981 | 28354 | 46654710 |
FDA Adverse Event Reporting System (Male)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| ATC | B05XB03 | BLOOD AND BLOOD FORMING ORGANS BLOOD SUBSTITUTES AND PERFUSION SOLUTIONS I.V. SOLUTION ADDITIVES Amino acids |
| ATC | V03AF11 | VARIOUS ALL OTHER THERAPEUTIC PRODUCTS ALL OTHER THERAPEUTIC PRODUCTS Detoxifying agents for antineoplastic treatment |
| CHEBI has role | CHEBI:27027 | trace elements |
| CHEBI has role | CHEBI:35623 | antiepileptic |
| CHEBI has role | CHEBI:50733 | nutritional supplement |
| CHEBI has role | CHEBI:75771 | mus musculus metabolite |
| CHEBI has role | CHEBI:75772 | baker's yeast metabolite |
| CHEBI has role | CHEBI:76924 | plant metabolites |
| CHEBI has role | CHEBI:76971 | e.coli metabolites |
| CHEBI has role | CHEBI:77746 | h. sapiens metabolites |
| CHEBI has role | CHEBI:84735 | algal metabolites |
| CHEBI has role | CHEBI:83056 | daphnia magna metabolites |
Drug Use (View source of the data)
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| Partial Central Diabetes Insipidus | indication | ||
| Classical phenylketonuria | contraindication | 7573000 | |
| Poisoning by digitalis glycoside | contraindication | 12876009 | |
| Sarcoidosis | contraindication | 31541009 | DOID:11335 |
| End stage renal disease | contraindication | 46177005 | DOID:784 |
| Humoral hypercalcemia of malignancy | contraindication | 47709007 | |
| Heart disease | contraindication | 56265001 | DOID:114 |
| Hypercalcemia | contraindication | 66931009 | DOID:12678 |
| Ventricular fibrillation | contraindication | 71908006 | |
| Hypercalciuria | contraindication | 71938000 | |
| Kidney disease | contraindication | 90708001 | DOID:557 |
| Kidney stone | contraindication | 95570007 |
Acid dissociation constants calculated using MoKa v3.0.0
| Dissociation level | Dissociation constant | Type (acidic/basic) |
|---|---|---|
| pKa1 | 1.99 | acidic |
| pKa2 | 10.46 | Basic |
| pKa3 | 9.86 | Basic |
Orange Book patent data (new drug applications)
None
Orange Book exclusivity data (new drug applications)
None
Bioactivity Summary:
| Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
|---|---|---|---|---|---|---|---|---|---|
| Glutathione reductase, mitochondrial | Enzyme | Ki | 4.26 | CHEMBL |
External reference:
| ID | Source |
|---|---|
| 4018682 | VUID |
| N0000146993 | NUI |
| D02304 | KEGG_DRUG |
| 657-27-2 | SECONDARY_CAS_RN |
| 4018682 | VANDF |
| 4018689 | VANDF |
| C0024337 | UMLSCUI |
| CHEBI:133538 | CHEBI |
| LYS | PDB_CHEM_ID |
| CHEMBL8085 | ChEMBL_ID |
| CHEMBL2105886 | ChEMBL_ID |
| D008239 | MESH_DESCRIPTOR_UI |
| DB00123 | DRUGBANK_ID |
| 724 | IUPHAR_LIGAND_ID |
| 6166 | INN_ID |
| K3Z4F929H6 | UNII |
| 5962 | PUBCHEM_CID |
| 6536 | RXNORM |
| 10705 | MMSL |
| 233693 | MMSL |
| 42619 | MMSL |
| 5002 | MMSL |
| d00488 | MMSL |
| 000931 | NDDF |
| 005151 | NDDF |
| 418834008 | SNOMEDCT_US |
| 734658000 | SNOMEDCT_US |
| 75799006 | SNOMEDCT_US |
Pharmaceutical products:
| Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
|---|---|---|---|---|---|---|---|---|
| CLINIMIX | HUMAN PRESCRIPTION DRUG LABEL | 16 | 0338-0180 | INJECTION | 464 mg | INTRAVENOUS | NDA | 21 sections |
| CLINIMIX | HUMAN PRESCRIPTION DRUG LABEL | 16 | 0338-0184 | INJECTION, EMULSION | 464 mg | INTRAVENOUS | NDA | 21 sections |
| CLINIMIX | HUMAN PRESCRIPTION DRUG LABEL | 16 | 0338-0188 | INJECTION | 464 mg | INTRAVENOUS | NDA | 21 sections |
| CLINIMIX | HUMAN PRESCRIPTION DRUG LABEL | 16 | 0338-0194 | INJECTION | 464 mg | INTRAVENOUS | NDA | 21 sections |
| CLINIMIX | HUMAN PRESCRIPTION DRUG LABEL | 16 | 0338-0198 | INJECTION | 348 mg | INTRAVENOUS | NDA | 21 sections |
| CLINIMIX E | HUMAN PRESCRIPTION DRUG LABEL | 21 | 0338-0202 | INJECTION | 464 mg | INTRAVENOUS | NDA | 20 sections |
| CLINIMIX E | HUMAN PRESCRIPTION DRUG LABEL | 21 | 0338-0206 | INJECTION | 464 mg | INTRAVENOUS | NDA | 20 sections |
| CLINIMIX E | HUMAN PRESCRIPTION DRUG LABEL | 21 | 0338-0210 | INJECTION | 464 mg | INTRAVENOUS | NDA | 20 sections |
| CLINIMIX E | HUMAN PRESCRIPTION DRUG LABEL | 21 | 0338-0214 | INJECTION | 464 mg | INTRAVENOUS | NDA | 20 sections |
| Travasol | HUMAN PRESCRIPTION DRUG LABEL | 15 | 0338-0644 | INJECTION | 580 mg | INTRAVENOUS | NDA | 20 sections |
| CLINIMIX | HUMAN PRESCRIPTION DRUG LABEL | 16 | 0338-1089 | INJECTION | 247 mg | INTRAVENOUS | NDA | 21 sections |
| CLINIMIX | HUMAN PRESCRIPTION DRUG LABEL | 16 | 0338-1091 | INJECTION | 247 mg | INTRAVENOUS | NDA | 21 sections |
| CLINIMIX | HUMAN PRESCRIPTION DRUG LABEL | 16 | 0338-1099 | INJECTION | 290 mg | INTRAVENOUS | NDA | 21 sections |
| CLINIMIX | HUMAN PRESCRIPTION DRUG LABEL | 16 | 0338-1101 | INJECTION | 290 mg | INTRAVENOUS | NDA | 21 sections |
| CLINIMIX E | HUMAN PRESCRIPTION DRUG LABEL | 21 | 0338-1113 | INJECTION | 247 mg | INTRAVENOUS | NDA | 20 sections |
| CLINIMIX E | HUMAN PRESCRIPTION DRUG LABEL | 21 | 0338-1115 | INJECTION | 247 mg | INTRAVENOUS | NDA | 20 sections |
| CLINIMIX E | HUMAN PRESCRIPTION DRUG LABEL | 21 | 0338-1123 | INJECTION | 290 mg | INTRAVENOUS | NDA | 20 sections |
| CLINIMIX E | HUMAN PRESCRIPTION DRUG LABEL | 21 | 0338-1125 | INJECTION | 290 mg | INTRAVENOUS | NDA | 20 sections |
| CLINIMIX | HUMAN PRESCRIPTION DRUG LABEL | 16 | 0338-1133 | INJECTION | 247 mg | INTRAVENOUS | NDA | 21 sections |
| CLINIMIX | HUMAN PRESCRIPTION DRUG LABEL | 16 | 0338-1134 | INJECTION | 247 mg | INTRAVENOUS | NDA | 21 sections |
| CLINIMIX | HUMAN PRESCRIPTION DRUG LABEL | 16 | 0338-1137 | INJECTION | 290 mg | INTRAVENOUS | NDA | 21 sections |
| CLINIMIX | HUMAN PRESCRIPTION DRUG LABEL | 16 | 0338-1138 | INJECTION | 290 mg | INTRAVENOUS | NDA | 21 sections |
| CLINIMIX E | HUMAN PRESCRIPTION DRUG LABEL | 21 | 0338-1142 | INJECTION | 159 mg | INTRAVENOUS | NDA | 20 sections |
| CLINIMIX E | HUMAN PRESCRIPTION DRUG LABEL | 21 | 0338-1144 | INJECTION | 247 mg | INTRAVENOUS | NDA | 20 sections |
| CLINIMIX E | HUMAN PRESCRIPTION DRUG LABEL | 21 | 0338-1145 | INJECTION | 247 mg | INTRAVENOUS | NDA | 20 sections |
| CLINIMIX E | HUMAN PRESCRIPTION DRUG LABEL | 21 | 0338-1147 | INJECTION | 290 mg | INTRAVENOUS | NDA | 20 sections |
| CLINIMIX E | HUMAN PRESCRIPTION DRUG LABEL | 21 | 0338-1148 | INJECTION | 290 mg | INTRAVENOUS | NDA | 20 sections |
| Effervescent Potassium Chloride | HUMAN PRESCRIPTION DRUG LABEL | 3 | 0603-3508 | TABLET, EFFERVESCENT | 1.50 g | ORAL | unapproved drug other | 17 sections |
| Kabiven | HUMAN PRESCRIPTION DRUG LABEL | 24 | 63323-712 | INJECTION, EMULSION | 263 mg | INTRAVENOUS | NDA | 25 sections |
| Perikabiven | HUMAN PRESCRIPTION DRUG LABEL | 24 | 63323-714 | INJECTION, EMULSION | 187 mg | INTRAVENOUS | NDA | 25 sections |